TABLE 1.
Demographic information, clinical characteristics, and erythrocytic biomarker levels.
| HC | PD | Significance | |
| Number of subjects | 79 | 124 | |
| Age (mean ± SD) | 62.6 ± 7.9 | 61.2 ± 8.5 | 0.6641 |
| Sex (men: women) | 44: 35 | 67: 57 | 0.8162 |
| MDS-UPDRS III (median, range, N = 74) | NA | 40.0 (8–73) | NA |
| HAMA (median, range, N = 70) | NA | 14 (3–47) | NA |
| HAMD (median, range, N = 70) | NA | 14 (2–54) | NA |
| H&Y (median, range, N = 90) | NA | 3 (1–5) | NA |
| MMSE (median, range, N = 67) | NA | 27 (16–30) | NA |
| MoCA (median, range, N = 67) | NA | 22.5 (6–29) | NA |
| Erythrocytic α-syn (mean ± SD, ng/mL) | 645.0 ± 248.0 | 1520.5 ± 824.5 | <0.0013 |
| Erythrocytic oligomeric α-syn (mean ± SD, ng/mL) | 135.0 ± 42.2 | 218.1 ± 86.5 | <0.0013 |
1Based on Mann–Whitney test.
2Based on Chi-square test.
3Based on univariate general linear model with the controlling of age and sex.
All significant p-values are highlighted by bold characters.
HC, healthy control; PD, Parkinson’s disease; MDS-UPDRS III, Movement Disorder Society sponsored Unified Parkinson’s Disease Rating Scale Part-III; α-syn, α-synuclein.